Mesylate Salt Compound (S) - 2 - (4 - (3 - fluoro - Benzyloxy) - (Benzylamino) - propionamide, polymorphic form (nf6), Pharmaceutical Composition and Use thereof for the preparation of a Drug and its Preparation Process

摘要

1. Dihydrate (s) - 2 - [4 - (3-fluoro-benzene-benzene-benzene) - benzene The second requirement: the compound is consistent with the first requirement, and its crystal transformation nf6 is characterized by the XRD peak value of 17.9 degrees,Page: 1Page: 120.7 degrees and 23.0 seconds (using 2teta of cu-kalfa1 radiation + - 0.1 degrees to - 5 degrees Celsius). The third requirement: according to any requirement 1 to 2, the compound is characterized by XRD powder peak value of 7.9 degrees,Page: 1Page: 1Page: 120.1%20.7 degreesPage: 1Page: 123.5 ° and 24.8 ° (in 2theta using Cu-Kalfa1 radiation, + - 0.1 ° to -5 ° C). Claim 4: The compound according to any of claims 1 to 3, characterized by the following XRD data according to table (1). Claim 7: A pharmaceutical composition according to claim 6 comprising 1% to 99% mesylate anhydrate of (S) -2- [4- (3-fluoro-benzyloxy) -benzylamino] -propionamide in its NF6 crystalline modification of according to any of claims 2 to 5 and 1% to 99% of mesylate anhydrate of (S) -2- [4- (3-fluoro-benzyloxy) -benzylamino] -propionamide in its crystalline modification A1, characterized by XRD peaks comprising 18.6 °,20.3 degrees20.6 degrees and 22.8 degrees (using cu-kalfa1 radiation + - 0.1 degrees)Preference, characterized by a peak XRD of 7.8 degrees,12.0 degrees 15.6 degrees17.7 degrees18.6 degreesPage: 120.3 degrees20.6 degrees22 8 y 29 0 (en 2theta usando radiacion Cu-Kalfa1 2B- 0 1) e incluso con mayor preferencia caracterizado por los siguientes datos de XRD segun la tabla (2) Reivindicacion 9 Uso de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 Monoamine oxidase B inhibitors and / or dopamine reabsorption inhibitors. Item 11: drugs provided in accordance with item 10 labor requirements for the treatment and / or prevention of certain physiological conditions and / or physiological pathology, including: central nervous system disorders, epilepsy, Parkinson's disease, neurodegenerative process, depression, spasm, hypnosis, Anal sex, chronic pain, neuralgia, dizziness, immigration, headache, concussion, cluster headache, neurons, hemispheric, facial pain, spider ophthalmia, severe headache, restless leg symptoms, addiction, exercise anxiety, tickling, burning,Tension, substance abuse, severe alcoholism, under reward syndrome, cognitive impairment, autism, dyslexia, attention deficit, hypertension, anxiety, schizophrenia, obsessive-compulsive dementia, psychosis, bipolar disorder, Tourette syndrome, moderate cognitive impairment and disorder Learning in children, adolescents and adults, age-related memory changes, age-related cognitive decline, Alzheimer's disease, Down's syndrome, traumatic brain injury, Huntington's disease, progressive paralysis, HIV, cerebrovascular accidents, vascular diseases,Pick or Creutzfeldt-Jacob disease, multiple sclerosis. Claim 15: Process for preparing the NF6 crystalline modification of (S) -2- [4- (3-fluoro-benzyloxy) -benzylamino] -propionamide mesylate anhydrate according to any of claims 2 to 5 comprising the steps of : (a) incubate mesylate anhydrate of (S) -2- [4- (3-fluoro-benzyloxy) -benzylamino] -propionamide crystalline modification A1 at = 0 ° C for one or several milliseconds or seconds or minutes or hours or days,O (b) incubate dihydroacid (s) - 2 - [4 - (3-fluoro-benzene) - benzene] Propionamide, as a component of the mixture, which contains at least one additional A lt component; = 0 milliseconds or seconds or minutes or days.